The Highest Dose of Wegovy Available in the UK

You've been on Wegovy for months and your prescriber has mentioned going higher — here's what that means

A common misunderstanding is that Wegovy's job is simply to get you to the highest dose as fast as possible. It isn't. The titration schedule exists because your digestive system needs time to adjust. Nausea, reflux and stomach discomfort are most likely when semaglutide first arrives in your system or when the dose steps up; moving slowly through the lower doses gives those effects the best chance of settling before you add more. Most people find the GI side effects are at their worst for the first week or two after a change and then fade.

The licensed Wegovy schedule runs 0.25mg for the first four weeks, then 0.5mg, 1.0mg and 1.7mg, each held for roughly four weeks, before reaching the 2.4mg maintenance dose most patients are familiar with. The step to 7.2mg is an additional tier that sits above this, and it is only for adults whose BMI is 30 or higher, the MHRA's approval does not extend to the lower BMI threshold or to Wegovy's cardiovascular indication. Your prescriber, not you, decides when and whether that final step is appropriate. You can read more about the full dose range on our Wegovy doses overview.

If you are wondering whether 2.4mg was the ceiling, it was, until early 2026. The landscape changed when the MHRA approved the 7.2mg dose in January 2026, initially available via three 2.4mg pens taken together weekly. A dedicated single-dose 7.2mg pen followed on 14 April 2026, offering a single weekly injection rather than three simultaneous ones. The MHRA's announcement of the single-dose 7.2mg pen confirmed its approval for weight management in adults with obesity.

What the evidence says about losing weight at the highest Wegovy dose

Trials at 7.2mg reported an average body-weight reduction of around 20.7% over 72 weeks. That is a meaningful step up from the roughly 15% average seen with the 2.4mg dose in the STEP 1 trial, published in the New England Journal of Medicine, and it narrows the gap with tirzepatide 15mg, which produced around 20–21% average weight reduction in SURMOUNT-1. These are population averages from controlled trials; individual results vary, and no medicine produces identical outcomes for every person. Your starting weight, diet, activity and how well you tolerate the treatment all shape what happens.

The side-effect profile at 7.2mg is broadly similar to lower doses, though GI effects can be more pronounced. Nausea, vomiting, diarrhoea, constipation and indigestion are the most commonly reported. They tend to be worst shortly after a dose increase and improve over time for most people. One thing worth knowing: the MHRA issued a Drug Safety Update in January 2026 specifically noting that acute pancreatitis is a known, if infrequent, side effect of GLP-1 medicines, severe, persistent stomach pain that reaches the back is a reason to seek urgent medical help, not to wait and see. You can find a broader look at how semaglutide compares to other medicines on our highest dose of semaglutide page.

It is also worth understanding that if you have not lost at least 5% of your body weight after six months on your highest tolerated dose, continuing is typically reviewed. This is built into NICE's guidance on semaglutide (NICE TA875) and reflects sound clinical practice: the medicine should be doing meaningful work, not just running in the background.

How dose increases are managed, and why that process matters as much as the number

Knowing what the highest Wegovy dose is and actually reaching it safely are two different things. A prescriber needs to see evidence that you are tolerating your current dose before moving you up. At a regulated service, each dose review involves a genuine clinical assessment, your weight, any side effects you have reported, and whether there are reasons to pause or adjust the plan. It is not automatic, and it should not be.

Dose timing matters too. Most prescribers follow a minimum four-week interval between increases, which aligns with the licensed schedule. If you want to understand the specifics of when increases typically happen and what prompts a pause, our page on how often Wegovy doses are increased goes into that in detail. The principle, though, is straightforward: slower is usually safer, and pushing through side effects to reach a higher dose faster tends to make people give up the treatment altogether.

Questions about cost at each stage of treatment are common, and fairly so. If you are thinking about what private Wegovy treatment typically costs across the dose schedule, including at the highest dosage of Wegovy, our Wegovy cost page covers what the market looks like and what an all-in price should include. Our prescribers review every consultation personally (the same day it is submitted) so if you want to explore whether Wegovy is right for you, the best place to start is a free consultation.